The Board of Directors have approved the Standalone Unaudited Financial Results for the quarter ended on 30th June 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
BDH Industries' Board of Directors approved standalone unaudited financial results for Q1 FY26 (quarter ended 30 June 2025) at a meeting held on 8 August 2025. Revenue from operations rose to ₹1,862.42 lakhs from ₹1,625.82 lakhs in Q1 FY25, a growth of about 14.6% year-on-year. Profit after tax (PAT) increased to ₹182.66 lakhs from ₹156.85 lakhs, up roughly 16.4% YoY, with EPS of ₹3.17 versus ₹2.17. The Pharmaceutical segment remains the core business with ₹1,830.22 lakhs in revenue, while Renewable Energy contributed ₹32.20 lakhs. The statutory auditor CLB & Associates issued an unmodified (clean) limited review report with no qualifications or emphasis of matter.
Steady double-digit growth in both revenue and profit with a clean audit opinion is a positive signal for shareholders, indicating stable operations. The modest scale of the company and reliance on the pharmaceutical segment remain key things for investors to watch.